id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-324364-9p04oeac	Hasan, Syed Shahzad	Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis	2020-09-12		.txt	text/plain	7998	314	40	Original, observational (prospective or retrospective) studies Included patients with coronavirus disease 2019 (COVID19) Documented use of either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) Reported frequency, percentage, and/or adjusted estimate of mortality or disease severity and/or adverse clinical outcomes (septic shock, admission to intensive care units) associated with COVID-19 From any region or language The reported odds ratios (ORs) and hazard ratios (HRs) that had been adjusted for potential covariates in the respective original studies and the corresponding 95% confidence intervals (CIs) were extracted and pooled in a random-effects model to estimate the association between the use of ACEIs/ ARBs and the risk of mortality and severe/critical illness in COVID-19 patients. In fact, the other studies [52, 78, 80, 84] included in the subgroup pooled analysis reported no difference in the risk of severe/ critical illness with the use of ACEIs compared to non-use of the ACEIs. A key strength of this systematic review and meta-analysis was the pooling of adjusted estimates on the mortality and severe/critical outcomes from the use of RAS inhibitors in COVID-19 patients.	./cache/cord-324364-9p04oeac.txt	./txt/cord-324364-9p04oeac.txt